Pimobendan
Introduction
Name
- USAN.
- rINN.
Class of drug
- Positive inotrope.
- Vasodilator.
Description
Chemical name
- 4,5-Dihydro-6-[2-(p-methyoxyphenyl)-5-benzimidazolyl]-5-methyl-3(2H-pyridazinone).
Molecular formula
- C19H18N4O2.
Molecular weight
- 334.4.
Storage requirements
- Do not store above 25°C.
- Store in a dry place.
- Vials are single use.
Uses
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Administration
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Pharmacokinetics
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Precautions
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Withdrawal Periods
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Adverse Reactions
Subscribe To View
This article is available to subscribers.
Try a free trial today or contact us for more information.
Further Reading
Publications
Refereed papers
- Recent references from VetMedResource and PubMed.
- Boswood A, Haggstrom J, Gordon S et al (2016) Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.��� JVIM 30, 1765-1779 PubMed.
- Summerfield N, Boswood A, O’Grady M, Gordon S, Dukes-McEwan J, Oyama M, Smith S, Patteson M, French A, Culshaw G, Braz-Ruivo L, Estrada A, O’Sullivan M, Loureiro J, Willis R and Watson P (2012) Efficacy of Pimobendan in the Prevention of Congestive Heart Failure or Sudden Death in Doberman Pinschers with Preclinical Dilated Cardiomyopathy (The PROTECT Study). J Vet Intern Med 26, 1337-1349 PubMed.
- Bernay F, Bland J M et al (2010) Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. JVIM 24, 331-341 PubMed.
- Atkins C, Bonagura S et al (2009) Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. ACVIM consensus statement. JVIM 23, 1142-1150 PubMed.
- Haggstrom J, Boswood A et al (2008) Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous valvular disease: The QUEST study. JVIM 22, 1124-1135 PubMed.
- O'Grady M R, Minors S L et al (2009) Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy. JVIM 22, 897-904 PubMed.
- Smith P J, French A et al (2005) Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease. JSAP 46, 121-130.
Other sources of information
- The Veterinary Formulary. 5th edn (2001) Ed: Bishop Y. British Veterinary Association and Pharmaceutical Press.
- Lombard C W et al (2000) Clinical experience with pimobendan. VCS Proceedings. Spring Meeting, UK.
- Luis Fuentes V, Kleeman R et al (1998) The effect of a novel inodilator pimobendan on heart failure status in Cocker Spaniels and Dobermanns with idiopathic dilated cardiomyopathy. Proccedings of the BSAVA Congress. p 284.
- Vetmedin Technical Dossier published by Boehringer Ingelheim Vetmedica.